Cellectis
Develops allogeneic, or 'off-the-shelf', CAR T-cell immunotherapies for cancer.
ALCLS | PA
Overview
Corporate Details
- ISIN(s):
- FR0010425595 (+2 more)
- LEI:
- 5493000KKX5VQ37Q2W83
- Country:
- France
- Address:
- 8 RUE DE LA CROIX JARRY, 75013 PARIS
- Website:
- https://cellectis.com/en
- Sector:
- Manufacturing
Description
Cellectis is a clinical-stage biopharmaceutical company specializing in the development of immunotherapies to treat cancer. The company leverages its proprietary gene-editing platform, TALEN®, to engineer Chimeric Antigen Receptor (CAR) T-cells. Its primary focus is on creating allogeneic, or 'off-the-shelf', CAR T-cell product candidates. These therapies are derived from T-cells from healthy donors and are designed to be broadly available for a large number of patients, in contrast to autologous therapies custom-made for each individual. The TALEN® technology is used to address key challenges in allogeneic cell therapy, including preventing Graft-versus-Host Disease and mitigating rejection by the patient's immune system.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-10-07 22:30 |
Information mensuelle relative au nombre total des droits de vote et d’actions …
|
French | 72.8 KB | ||
| 2020-10-07 22:30 |
Monthly information on share capital and company voting rights
|
English | 71.6 KB | ||
| 2020-09-07 22:30 |
Information mensuelle relative au nombre total des droits de vote et d’actions …
|
French | 75.4 KB | ||
| 2020-09-07 22:30 |
Monthly information on share capital and company voting rights
|
English | 71.2 KB | ||
| 2020-09-02 22:57 |
Cellectis to Participate in Upcoming Investor Conferences
|
English | 94.1 KB | ||
| 2020-08-05 22:30 |
Cellectis publie ses résultats financiers pour le deuxième trimestre et le prem…
|
French | 353.4 KB | ||
| 2020-08-05 22:30 |
Cellectis Provides Business Update and Reports Financial Results for Second Qua…
|
English | 450.2 KB | ||
| 2020-07-29 22:30 |
Cellectis organise une conférence téléphonique pour présenter ses résultats fin…
|
French | 78.6 KB | ||
| 2020-07-29 22:30 |
Cellectis to Hold Second Quarter 2020 Earnings Call on Thursday, August 6, 2020…
|
English | 54.6 KB | ||
| 2020-07-29 10:04 |
Franchissement de seuils
|
French | 115.2 KB | ||
| 2020-07-21 22:30 |
Cellectis nomme Dr Steve Doares, vétéran de l’industrie biopharmaceutique, Vic…
|
French | 69.9 KB | ||
| 2020-07-21 22:30 |
Cellectis Appoints Biopharma Veteran Steve Doares, Ph.D., as Senior Vice Presid…
|
English | 84.0 KB | ||
| 2020-07-11 00:04 |
Monthly information on share capital and company voting rights
|
English | 48.9 KB | ||
| 2020-07-06 23:19 |
Pour se concentrer pleinement sur Cellectis, André Choulika se retire du Consei…
|
French | 74.6 KB | ||
| 2020-07-06 23:19 |
To Fully Focus on Cellectis, Dr. André Choulika Retires From Calyxt’s Board of …
|
English | 95.3 KB |
Automate Your Workflow. Get a real-time feed of all Cellectis filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cellectis
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cellectis via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
